Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Athenagen has closed its merger with Zapaq, creating a combined company that unites two' extensive R&D programs to form what Athenagen hopes will become a leading neurovascular therapeutics pipeline.
Subscribe to our email newsletter
South San Francisco-headquartered Athenagen is engaged in the discovery and development of small-molecule drugs to treat neurovascular disease indications, such as Alzheimer’s disease, age-related macular degeneration (AMD) and cognitive disorders.
The privately-held company has two fundamental technology platforms: beta-secretase inhibitors for the treatment of Alzheimer’s disease; and nACh receptor agonists and antagonists for the treatment of angiogenesis-mediated diseases and cognitive disorders.
Athenagen currently has four product development programs based on these two technologies, namely ATG003, a topical anti-angiogenesis compound for neovascular AMD; GTS-21, an oral agonist of the alpha-7 nACh receptor pathway for cognition enhancement; ATG002, a topical pro-angiogenesis compound for diabetic foot ulcers; and two clinical candidates from the beta-secretase inhibitor program that will be studied in Alzheimer’s disease.
Terms of the merger were not disclosed.